Clinical trial of directly vascularized islet cell replacement therapy for high-risk type 1 diabetes

**Disease Area:** Type 1 diabetes

**Investigator:** Howard Foyt

**Institution:** ViaCyte, Inc.

**CIRM Grant:** CLIN2-09672

**Award Value:** $19,752,463

**Trial Sponsor:** ViaCyte, Inc.

**Trial Stage:** Phase 1/2

**Trial Status:** Recruiting

**Targeted Enrollment:** 55

**ClinicalTrials.gov ID:** NCT03163511

**Details:**
ViaCyte is developing cell therapies to replace lost beta cells for people with type 1 diabetes (T1D). The therapies are derived from human embryonic stem cells, which are partially matured into becoming pancreatic tissues (the type destroyed in T1D). The cells are inserted into a small pouch that is transplanted under the patient's skin. The transplanted cells will develop into fully matured beta cells that secrete the hormone insulin, which is needed to keep blood sugar levels at a healthy level. CIRM is funding ViaCyte's two Phase 1/2 trials testing its product candidate, PEC-Direct (aka VC-02), which allows the patient's blood vessels to make direct contact with the implanted cells. PEC-Direct is being developed for patients with high-risk T1D.

**Goal:**
Safety, Tolerability, Efficacy.

**Updates:**
This study is currently recruiting participants.

**News about this clinical trial:**
ViaCyte Awarded New CIRM Grant to Support Clinical Trial of PEC-Direct Product Candidate for High-Risk Type 1 Diabetes

Source URL: https://www.cirm.ca.gov/clinical-trial/clinical-trial-directly-vascularized-islet-cell-replacement-therapy-high-risk-type-1-diabetes